Statistical Considerations for Clinical Trials During COVID-19: Confirmatory Adaptive Platform Trial (CAPT) Design for COVID-19 Treatment (Part II)

LinkedIn respects your privacy

LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads) on and off LinkedIn. Learn more in our Cookie Policy.

Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings.

Qing Liu, Ph.D., ASA Fellow’s Post

Qing Liu, Ph.D., ASA Fellow

5y Edited

This is the part II of the article that describes confirmatory adaptive platform trial (CAPT) design for COVID-19 treatment development. We describe the methodological foundation of adaptive designs. We provide statistical methods for CAPT design, covering topics on sequential randomizations, adaptive group sequential designs, and sample size adjustment.

Statistical Considerations for Clinical Trials During COVID-19: Confirmatory Adaptive Platform Trial (CAPT) Design for COVID-19 Treatment (Part II) Qing Liu, Ph.D., ASA Fellow on LinkedIn

To view or add a comment, sign in

Explore content categories

LinkedIn respects your privacy

Qing Liu, Ph.D., ASA Fellow’s Post

More from this author

Systematic Bias in a Randomized Trial of Hydroxychloroquine as Post-exposure Prophylaxis for COVID-19

Statistical Considerations for Clinical Trials During COVID-19: Confirmatory Adaptive Platform Trial (CAPT) Design for COVID-19 Treatment

Statistical Considerations for Clinical Trials During COVID-19: Confirmatory Adaptive Platform Trial (CAPT) Design for COVID-19 Treatment (Part III)

Explore content categories